Morepen Labs - Morepen Laboratories Share Price

50.122.83 (5.99%)

Closed
As On: 12 Jun, 2026, 03:59 PM IST
As On: 12 Jun, 2026, 03:58 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	48.26
High	51.49
Low	48.21
Prev Close	47.29
Volume	1,82,07,733
VWAP(₹)	49.79

Share Price	Value
Today/Current/Last	50.1250.15
Previous Day	47.2947.27

Morepen Labs Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Morepen Labs Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	493.18	487.97	416.21	429.65	470.46
Total Income Growth (%)	1.07	17.24	-3.13	-8.68	2.70
Total Expenses	466.02	448.23	366.34	410.09	440.08
Total Expenses Growth (%)	3.97	22.35	-10.67	-6.81	4.39
EBIT	27.16	39.74	49.88	19.55	30.39
EBIT Growth (%)	-31.65	-20.32	155.06	-35.65	-16.86
Profit after Tax (PAT)	15.74	27.51	40.87	10.75	20.32
PAT Growth (%)	-42.77	-32.70	280.29	-47.09	-23.88
EBIT Margin (%)	5.51	8.14	11.98	4.55	6.46
Net Profit Margin (%)	3.19	5.64	9.82	2.50	4.32
Basic EPS (₹)	0.28	0.50	0.75	0.20	0.35

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	471.63	461.50	374.18	395.38	385.08
Total Income Growth (%)	2.19	23.34	-5.36	2.67	-5.65
Total Expenses	440.13	425.78	351.21	380.21	364.03
Total Expenses Growth (%)	3.37	21.23	-7.63	4.44	-3.31
EBIT	31.50	35.73	22.97	15.16	21.05
EBIT Growth (%)	-11.84	55.55	51.47	-27.95	-33.49
Profit after Tax (PAT)	20.12	23.50	14.38	8.06	11.91
PAT Growth (%)	-14.35	63.42	78.35	-32.32	-47.50
EBIT Margin (%)	6.68	7.74	6.14	3.84	5.47
Net Profit Margin (%)	4.27	5.09	3.84	2.04	3.09
Basic EPS (₹)	0.37	0.43	0.26	0.15	0.20

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	1,827.01	1,829.94	1,704.40	1,423.66	1,557.13
Total Revenue Growth (%)	-0.16	7.37	19.72	-8.57	29.75
Total Expenses	1,732.91	1,674.83	1,568.99	1,367.91	1,430.43
Total Expenses Growth (%)	3.47	6.75	14.70	-4.37	29.85
Profit after Tax (PAT)	94.88	118.02	96.16	38.68	101.68
PAT Growth (%)	-19.61	22.73	148.63	-61.96	4.73
Operating Profit Margin (%)	6.11	9.02	8.23	4.07	7.71
Net Profit Margin (%)	5.25	6.51	5.68	2.72	6.57
Basic EPS (₹)	1.73	2.20	1.88	0.77	2.26

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	1,702.69	1,570.25	1,550.16	1,344.64	1,459.50
Total Revenue Growth (%)	8.43	1.30	15.28	-7.87	29.83
Total Expenses	1,614.52	1,432.67	1,401.18	1,281.60	1,333.96
Total Expenses Growth (%)	12.69	2.25	9.33	-3.93	29.52
Profit after Tax (PAT)	66.06	101.58	110.94	46.24	101.06
PAT Growth (%)	-34.97	-8.44	139.90	-54.24	7.23
Operating Profit Margin (%)	6.20	9.30	9.91	4.85	8.15
Net Profit Margin (%)	3.92	6.53	7.21	3.45	6.97
Basic EPS (₹)	1.21	1.90	2.17	0.92	2.25

All figures in Rs Cr, unless mentioned otherwise

Insights

Topline Contraction
Sales de-grew by 0.16%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 12.89% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	1,936.12	1,778.10	1,293.21	1,110.50	1,070.05
Total Assets Growth (%)	8.89	37.50	16.45	3.78	24.69
Total Liabilities	689.03	591.14	445.98	358.05	491.95
Total Liabilities Growth (%)	16.56	32.55	24.56	-27.22	13.39
Total Equity	1,247.09	1,186.96	847.23	752.45	578.10
Total Equity Growth (%)	5.07	40.10	12.60	30.16	36.25
Current Ratio (x)	2.37	2.32	2.21	2.35	1.61
Total Debt to Equity (x)	0.16	0.07	0.03	0.03	0.03
Contingent Liabilities	0.00	37.76	22.71	11.84	20.62

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	1,907.66	1,721.20	1,279.31	1,105.54	1,033.26
Total Assets Growth (%)	10.83	34.54	15.72	7.00	21.92
Total Liabilities	664.90	539.70	390.28	325.43	435.09
Total Liabilities Growth (%)	23.20	38.29	19.93	-25.20	8.09
Total Equity	1,242.76	1,181.50	889.02	780.11	598.17
Total Equity Growth (%)	5.18	32.90	13.96	30.42	49.09
Current Ratio (x)	2.59	2.40	2.39	2.51	1.68
Total Debt to Equity (x)	0.16	0.07	0.03	0.03	0.03
Contingent Liabilities	0.00	35.68	20.04	11.84	18.98

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	32.64	32.06	73.37	-91.17	-57.76
Net Cash used in Investing Activities	-123.42	-321.51	-83.30	-46.51	-31.68
Net Cash flow from Financing Activities	97.40	299.89	5.20	143.54	63.85
Net Cash Flow	6.62	10.44	-4.72	5.86	-25.58
Closing Cash & Cash Equivalent	31.19	27.38	16.95	21.67	15.80
Closing Cash & Cash Equivalent Growth (%)	13.91	61.59	-21.79	37.10	-61.82
Total Debt/ CFO (x)	5.96	2.48	0.40	-0.28	-0.32

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	20.47	29.08	77.36	-102.12	-66.38
Net Cash used in Investing Activities	-119.02	-280.42	-83.60	-36.20	-22.64
Net Cash flow from Financing Activities	97.12	260.47	0.28	144.20	63.93
Net Cash Flow	-1.43	9.12	-5.96	5.88	-25.09
Closing Cash & Cash Equivalent	23.00	24.43	15.30	21.26	15.38
Closing Cash & Cash Equivalent Growth (%)	-5.85	59.62	-28.03	38.25	-62.00
Total Debt/ CFO (x)	9.46	2.72	0.36	-0.25	-0.28

All figures in Rs Cr, unless mentioned otherwise

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 32.64 cr is 0.34 times compared to the reported net profit of Rs 94.88 cr. (Source: Consolidated Financials)
Decrease in Cash from Investing
Company has used Rs 123.42 cr for investing activities which is an YoY decrease of 61.61%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	7.61	10.20	11.34	5.13	17.57
Return on Capital Employed (%)	7.64	12.79	15.61	7.31	19.44
Return on Assets (%)	4.90	6.63	7.43	3.48	9.50
Interest Coverage Ratio (x)	8.95	23.07	46.52	43.25	-19.96
Asset Turnover Ratio (x)	0.97	1.18	1.41	1.30	1.60
Price to Earnings (x)	19.53	22.22	22.37	34.01	17.21
Price to Book (x)	1.49	2.27	2.54	1.74	3.02
EV/EBITDA (x)	13.46	13.94	12.32	14.95	11.71
EBITDA Margin (%)	8.13	10.62	10.21	6.04	9.50

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	5.31	8.59	12.47	5.92	16.89
Return on Capital Employed (%)	7.28	11.48	16.45	7.98	18.74
Return on Assets (%)	3.46	5.90	8.67	4.18	9.78
Interest Coverage Ratio (x)	8.30	23.81	49.69	41.92	-18.92
Asset Turnover Ratio (x)	0.93	1.04	1.29	1.25	1.54
Price to Earnings (x)	28.09	25.84	19.42	28.41	17.33
Price to Book (x)	1.49	2.22	2.42	1.68	2.92
EV/EBITDA (x)	14.96	15.69	12.20	15.44	12.35
EBITDA Margin (%)	7.94	10.87	11.34	6.20	9.61

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Morepen Labs	28.95	2.20	7.61	7.64	4.90	8.58	6.11	5.29	1.73	2.37	0.16	5.96
Orchid Pharma	228.53	3.61	1.59	2.50	1.07	7.22	5.03	2.61	4.05	2.45	0.28	3.53
IOL Chemicals	28.63	2.19	7.65	11.07	5.32	1.42	9.06	5.93	4.69	1.78	0.07	0.62
Gufic BioSci	57.98	5.60	9.65	14.93	4.78	10.83	13.04	6.80	6.40	1.55	0.58	8.57
SMS Pharma	35.21	4.57	12.97	13.84	7.48	19.11	15.75	9.92	11.15	1.81	0.46	6.16
Add More

Annual Ratios (%)

Choose from Peers

Panacea Biotec
Unichem Labs
Solara Active Pharma
Indoco Remedies
Hikal Ltd

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Morepen Labs Stock Performance	5.99	16.53	19.90	27.76	-23.99	93.51	-14.83
Orchid Pharma Stock Performance	8.42	27.51	65.29	37.26	24.28	116.30	-38.13
IOL Chemicals Stock Performance	5.01	22.76	47.14	83.09	55.60	52.15	8.16
Gufic BioSci Stock Performance	5.12	29.58	27.67	28.66	-0.96	82.43	86.09
SMS Pharma Stock Performance	1.13	-4.02	-6.04	2.95	46.06	345.10	150.29
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	19,53,71,588	35.65 %	0.00
Pledge	0	0.00 %	0.00
FII	86,84,961	1.59 %	-0.03
DII	51,59,414	0.94 %	0.00
MF	15,884	0.00 %	0.00
Others	33,87,37,736	61.82 %	0.02

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	35.65	35.65	35.65	35.65
Pledge	0.00	0.00	0.00	0.00
FII	1.59	1.62	1.62	1.72
DII	0.94	0.94	0.94	0.94
Mutual Funds	0.00	0.00	0.00	0.00
Others	61.82	61.79	61.79	61.69

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Motilal Oswal BSE Healthcare ETF-G
Equity: Sectoral-Pharma
- 0.04
  Amount Invested (in Cr.)
- 0.10179381%
  % of AUM
- -3.67
  % Change (MoM basis)
Bandhan BSE Healthcare Index Direct-G
Equity: Sectoral-Pharma
- 0.02
  Amount Invested (in Cr.)
- 0.1%
  % of AUM
- 5.90
  % Change (MoM basis)
Motilal Oswal BSE 1000 Index Direct-G
Equity: Flexi Cap
- 0.00
  Amount Invested (in Cr.)
- 0.00715863%
  % of AUM
- 3.92
  % Change (MoM basis)

View all Mutual Fund Schemes

Corporate Actions

Recent
Final
10%
May 26, 2026
Board Meeting
Audited Results & Final Dividend
May 21, 2026
Board Meeting
Audited Results
May 21, 2026

Board Meetings

Announced on	Meeting on
May 21, 2026	May 26, 2026
Audited Results & Final Dividend
May 21, 2026	May 22, 2026
Audited Results
Feb 03, 2026	Feb 10, 2026
Quarterly Results
Nov 07, 2025	Nov 14, 2025
Quarterly Results
Aug 01, 2025	Aug 06, 2025
Quarterly Results & Others

Dividends
Announced on Ex-Date Dividend%
May 12, 2025 Aug 29, 2025 10%
Jul 01, 2002 Sep 18, 2002 30%
Jun 15, 2001 Sep 03, 2001 10%
Jan 16, 2001 Jan 24, 2001 25%
May 26, 2026 - 10%
Bonus
No Data Available
Splits
Announced on Ex-Date
Oct 12, 2000 Nov 07, 2000
Split: Old FV10.0| New FV:2.0
Rights
Announced on Ex-Date
Apr 12, 1996 Sep 09, 1996
Rights ratio: 1 share for every 1 held at a price of Rs 100.0
AGM/EGM Meetings
Announced on Meeting on
Aug 06, 2025 Sep 06, 2025
-
Jan 17, 2025 Feb 10, 2025
-
Sep 11, 2024 Sep 28, 2024
A.G.M.
Feb 26, 2024 Mar 18, 2024
-
Sep 05, 2023 Sep 28, 2023
A.G.M.

Announced on	Ex-Date	Dividend%
May 12, 2025	Aug 29, 2025	10%
Jul 01, 2002	Sep 18, 2002	30%
Jun 15, 2001	Sep 03, 2001	10%
Jan 16, 2001	Jan 24, 2001	25%
May 26, 2026	-	10%

Announced on	Ex-Date
Oct 12, 2000	Nov 07, 2000
Split: Old FV10.0\| New FV:2.0

Announced on	Ex-Date
Apr 12, 1996	Sep 09, 1996
Rights ratio: 1 share for every 1 held at a price of Rs 100.0

Announced on	Meeting on
Aug 06, 2025	Sep 06, 2025
-
Jan 17, 2025	Feb 10, 2025
-
Sep 11, 2024	Sep 28, 2024
A.G.M.
Feb 26, 2024	Mar 18, 2024
-
Sep 05, 2023	Sep 28, 2023
A.G.M.

About Morepen Labs

Morepen Laboratories Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 2,746.34 Crore) operating in Pharmaceuticals sector.

Morepen Laboratories Ltd. key Products/Revenue Segments include API and Intermediates, Home Care, Formulations, Export Incentives, Other Operating Revenue for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 493.18 Crore, up 1.07 % from last quarter Total Income of Rs 487.97 Crore and up 4.83 % from last year same quarter Total Income of Rs 470.46 Crore. Company has reported net profit after tax of Rs 15.70 Crore in latest quarter.

The company’s top management includes Mr.Sushil Suri, Mr.Sanjay Suri, Mr.Praveen Kumar Dutt, Mr.Ranjit Khattar, Dr.(Mrs.)Savita, Mr.Sharad Jain, Mr.Ajay Kumar Sharma, Mr.Vipul Kumar Srivastava. Company has S P Babuta & Associates as its auditors. As on 31-03-2026, the company has a total of 54.80 Crore shares outstanding.

Morepen Labs Share Price Today is Rs. 50.12. On previous day, the Morepen Labs Share Price (NSE) closed at Rs. 47.29, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 35.65% of the stake in Morepen Labs shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Morepen Labs stocks was 1.59% as compared to 1.62% in Dec 2025 with decrease of 0.03%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.94% as compared to 0.94% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Morepen Labs shares 0.0% was held by mutual funds. The rest including public held is 61.82%. Morepen Labs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Morepen Labs Dividend: Ever since 1984, Morepen Labs dividends has been paid out around 10 times. As on 12 Jun, 2026, 03:59 PM IST, The overall dividend yield for Morepen Labs stands at 0.42%. The last dividend paid was on August 29, 2025 (Rs. 0.2). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 1.73.

Morepen Labs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 493.18 Cr. of sales and 1.07% of quarterly net profit, there have been multiple ups and downs in the Morepen Labs stock prices in the past few weeks. For example, Morepen Labs stock price on 5th of June 2026 was around Rs. 43.75. Morepen Labs share price now stands at an average of Rs. 50.12. Judging by last week's performance, stock is in up trend.

Morepen Labs has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Morepen Labs share.

Historical Prices and Performance:
Morepen Labs, incorporated in 1984 is a Small Cap company (with a market cap of Rs. 2746.34) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Morepen Labs stock was 7.61%, 10.2%, 11.34%, 5.13% and 17.57% respectively.
The Morepen Labs share gave a 3 year return of 85.29% as compared to Nifty 50 which gave a return of 26.99%.
Morepen Labs announced 10.0% final dividend on August 29, 2025.

Key Metrics:
PE Ratio of Morepen Labs is 27.31
Prices/Sales Ratio of Morepen Labs is 1.03
Price/Book Ratio of Morepen Labs is 2.08

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Morepen Labs, major competitors and peers include Orchid Pharma, IOL Chemicals, Gufic BioSci and SMS Pharma. As of Dec 2025, the dividend yield of Morepen Labs stands at 0.42% while Orchid Pharma, IOL Chemicals, Gufic BioSci and SMS Pharma stand at 0.0%, 0.74%, 0.03% and 0.1% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 27.31 and 2.08 respectively.

Leadership of Morepen Labs :
Vipul Kumar Srivastava is Co. Secretary & Compl. Officer
Ajay Kumar Sharma is Chief Financial Officer
Sushil Suri is Chairman & Managing Director
Sanjay Suri is Whole Time Director
Praveen Kumar Dutt is Independent Director
Savita is Independent Director
Ranjit Khattar is Independent Director
Sharad Jain is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

BSE SmallCap, BSE Healthcare, BSE AllCap, BSE Next 250 Microcap, BSE NEXT 500

Address

Morepen Village,Nalagarh Road,Solan District, Himachal Pradesh - 173205

Contact

investors@morepen.com

http://www.morepen.com

PE Ratio(x)	28.95
EPS - TTM(₹)	1.73
MCap(₹ Cr.)	2,746.34
MCap Rank	75
PB Ratio(x)	2.17
Div Yield(%)	0.40
Face Value(₹)	2.00
52W High(₹)	70.50
52W Low(₹)	33.05
MCap/Sales	1.03
Beta(1 Month)	2.21
BV/Share(₹)	22.76

PE Ratio(x)	28.96
EPS - TTM(₹)	1.73
MCap(₹ Cr.)	2,747.99
MCap Rank	75
PB Ratio(x)	2.08
Div Yield(%)	0.40
Face Value(₹)	2.00
52W High(₹)	70.40
52W Low(₹)	33.44
MCap/Sales	1.03
Beta(1 Month)	2.05
BV/Share(₹)	22.76

1 Day	5.99%
1 Month	16.72%
3 Months	24.49%
1 Year	-24.07%
3 Years	85.29%
5 Years	-21.93%

1 Day	6.09%
1 Month	16.82%
3 Months	24.47%
1 Year	-24.03%
3 Years	85.6%
5 Years	-21.88%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Morepen Labs - Morepen Laboratories Share Price

Key Metrics

Morepen Labs share price insights

Morepen Labs Share Price Returns

Morepen Labs Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Motilal Oswal BSE Healthcare ETF-G

Bandhan BSE Healthcare Index Direct-G

Motilal Oswal BSE 1000 Index Direct-G

Morepen Labs Top Searches

Corporate Actions

About Morepen Labs

Executive Leadership

Auditors

FAQs about Morepen Labs share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News